Literature DB >> 34223839

Generation of Zebrafish Larval Xenografts and Tumor Behavior Analysis.

Mayra Martinez-Lopez1, Vanda Póvoa2, Rita Fior3.   

Abstract

Zebrafish larval xenografts are being widely used for cancer research to perform in vivo and real-time studies of human cancer. The possibility of rapidly visualizing the response to anti-cancer therapies (chemo, radiotherapy, and biologicals), angiogenesis and metastasis with single cell resolution, places the zebrafish xenograft model as a top choice to develop preclinical studies. The zebrafish larval xenograft assay presents several experimental advantages compared to other models, but probably the most striking is the reduction of size scale and consequently time. This reduction of scale allows single cell imaging, the use of a relatively low number of human cells (compatible with biopsies), medium-high-throughput drug screenings, but most importantly enables a significant reduction of the time of the assay. All these advantages make the zebrafish xenograft assay extremely attractive for future personalized medicine applications. Many zebrafish xenograft protocols have been developed with a wide diversity of human tumors; however, a general and standardized protocol to efficiently generate zebrafish larval xenografts is still lacking. Here we provide a step-by-step protocol, with tips to generate xenografts and guidelines for tumor behavior analysis, whole-mount immunofluorescence, and confocal imaging quantification.

Entities:  

Year:  2021        PMID: 34223839     DOI: 10.3791/62373

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  2 in total

1.  XePhIR: the zebrafish xenograft phenotype interactive repository.

Authors:  A Groenewoud; G Forn-Cuní; F B Engel; B E Snaar-Jagalska
Journal:  Database (Oxford)       Date:  2022-04-28       Impact factor: 4.462

2.  Zebrafish Avatars of rectal cancer patients validate the radiosensitive effect of metformin.

Authors:  Bruna Costa; Laura M Fernandez; Oriol Parés; Ricardo Rio-Tinto; Inês Santiago; Mireia Castillo-Martin; Amjad Parvaiz; Rita Fior
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.